GIA632
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 15, 2025
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=84 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1